Literature DB >> 30557532

TUSARC: Prognostic Value of High-Sensitivity Cardiac Troponin T Assay in Asymptomatic Patients with High Cardiovascular Risk.

Diego Martín Raymondi1, Héctor Garcia2, Isabel Álvarez3, Luis Hernández4, Jorge Palazuelos Molinero5, Vicente Villamandos6.   

Abstract

BACKGROUND: Prognostic value of high-sensitivity cardiac troponin T (hs-cTnT) assays have been assessed in selected populations in different studies and in registries of members of the general population with low cardiovascular risk. The aim of this study was to determine the prognostic value of hs-cTnT in an asymptomatic very-high cardiovascular risk Spanish population.
METHODS: From a previous prospective cohort of the TUSARC (troponina T UltraSensible en pacientes Asintomáticos de alto Riesgo Cardiovascular) registry, follow-up was conducted in 602 patients (93.18%). The association of high hs-cTnT (≥99th percentile value) and incidence of primary event was studied. A primary event was defined as a combined major cardiovascular event (incidence of cardiovascular death, decompensated heart failure, non-fatal cerebrovascular event, non-fatal myocardial infarction, or coronary revascularization). The association between high hs-cTnT and incidence of secondary events was studied as well.
RESULTS: In patients with high hs-cTnT, the incidence of primary event during follow-up was significantly higher (18.30% vs 3.67% P < .001): heart failure (6.25% vs 0.73% P < .001), cardiovascular death (7.29% vs 0.00% P < .001), and death from any cause (7.81% vs 0.98% P < .001).
CONCLUSIONS: In an asymptomatic very-high cardiovascular risk Spanish population, elevated hs-cTnT was significantly associated with incident major cardiovascular combined end point and incidence of heart failure, cardiovascular death, and death from any cause.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular mortality; Cardiovascular risk; High-sensitivity cardiac T troponin; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30557532     DOI: 10.1016/j.amjmed.2018.11.035

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Lessons from spending on megestrol for cancer cachexia.

Authors:  Timothy J Brown; Sonal Gandhi; Thomas J Smith; Arjun Gupta
Journal:  Support Care Cancer       Date:  2021-04-24       Impact factor: 3.603

Review 2.  Advancements in biomarkers for cardiovascular disease: diagnosis, prognosis, and therapy.

Authors:  Nicholas Wettersten; Yu Horiuchi; Alan Maisel
Journal:  Fac Rev       Date:  2021-03-31

3.  The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review.

Authors:  Ty Sweeney; Renato Quispe; Thomas Das; Stephen P Juraschek; Seth S Martin; Erin D Michos
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-05-26

4.  Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.

Authors:  Paola Simeone; Romina Tripaldi; Annika Michelsen; Thor Ueland; Rossella Liani; Sonia Ciotti; Kåre I Birkeland; Hanne L Gulseth; Augusto Di Castelnuovo; Francesco Cipollone; Pål Aukrust; Agostino Consoli; Bente Halvorsen; Francesca Santilli
Journal:  Cardiovasc Diabetol       Date:  2022-03-11       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.